PBAC Public Summary Documents - July 2015

Page last updated: 19 February 2016

Public Summary Documents relating to the July 2015 PBAC meeting.

• Aciclovir; 30mg/g (3%) eye ointment, 4.5g; Acivision®
• Aclidinium bromide with eformoterol fumarate dehydrate; aclidinium 340 microgram/actuation + eformoterol 12 microgram/actuation inhalation: powder for, 60 actuations; Brimica® Genuair®
• Adalimumab; 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges; 40 mg/0.8 mL injection, 2 x 0.8 mL syringes; 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges; 40 mg/0.8 mL injection, 6 x 0.8 mL syringes; Humira®
• Afatinib dimaleate; 20 mg tablet, 28; 30 mg tablet, 28; 40 mg tablet, 28; 50 mg tablet, 28; Giotrif®
• Anakinra; anakinra 100 mg/0.67 mL injection, 28 x 0.67 mL syringes; Kineret®
• Bendamustine; powder for injection 100 mg vial, 1; powder for injection 25 mg vial, 1; Ribomustin®
• Bosentan; epoprostenol; macitentan; bosentan 62.5 mg tablet, 60; bosentan 125 mg tablet, 60; epoprostenol 500 microgram injection vial, 1; epoprostenol 1.5 mg injection vial, 1; macitentan 10 mg tablet, 30; Tracleer®; Veletr®; Opsumit®
• Brinzolomide with brimonidine tartrate; suspension containing brinzolamide 10 mg/mL + brimonidine 2 mg/mL, 5 mL; Simbrinza®
• Buprenorphine; 15 microgram/hour patch, 2; 25 microgram/hour patch, 2; 30 microgram/hour patch, 2; 40 microgram/hour patch, 2; Norspan®
• Carglumic acid; 200 mg dispersible tablet, 5; 200 mg dispersible tablet, 60; Carbaglu®
• Dapagliflozin and metformin XR; modified release; Xigduo® XR
• Deferasirox; 125 mg dispersible tablet, 28; 250 mg dispersible tablet, 28; 500mg dispersible tablet, 28; Exjade®
• Eliglustat; eliglustat tartrate 100 mg hard capsule (equivalent to 84 mg eliglustat), 56; Cerdelga®
• Exenatide; 2 mg, powder for injection, vial; Bydureon®
• Fentanyl citrate (sublingual); Abstral®
• Fentanyl citrate (buccal); Fentora®
• Glycomacropeptide and essential amino acids with vitamins and minerals; 15 g protein oral liquid, 30 x 250 mL tetra pack; Tylactin® RTD
• Ibrutinib; 140 mg capsules, 90; Imbruvica®
• Infliximab; 100 mg injection vial, 1; 100 mg injection vial, 3; 100 mg injection vial, 4; Inflectra®
• Insulin glargine; 300 unit/mL, 1 x 1.5 mL cartridge; 300 unit/mL, 3 x 1.5 mL cartridge; 300 unit/mL, 5 x 1.5 mL cartridge; Toujeo®
• Ivacaftor; 150 mg tablet, 56; Kalydeco®
• Leuprorelin; 45 mg injection: modified release [1 x 45 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1; Lucrin® Depot 6 month PDS
• Leuprorelin; 30 mg injection: modified release [1 x 30 mg syringe] (&) inert substance diluent [1 x 2 mL syringe], 1; Lucrin® Depot
• Mannitol; powder for inhalation, 40 mg capsules, 280, Bronchitol®
• Multicomponent Meningococcal Group B Vaccine (4CmenB); 0.5 mL suspension for injection pre-filled syringe; Bexsero®
• Nadroparin calcium; pre-filled syringe, 1900, 2850, 3800, 5700, 7600, 9500, 11400, 15200, 19,000 IU anti-Xa/mL; Fraxiparine® and Fraxiparine Forte®
• Netupitant and palonosetron; netupitant 300 mg + palonosetron 0.5 mg, 1; Akynzeo®
• Nitisinone; 2 mg capsule, 60; 5 mg capsule, 60; 10 mg capsule, 60; Orfadin®
• Nivolumab, concentrate solution for infusion, 10 mg/mL, 1 x 4 mL vial, concentrate solution for infusion, 10 mg/mL, 1 x 10 mL vial, Opdivo®
• Oxycodone and Naloxone; Targin®
• Paritaprevir with ritonavir, ombitasvir and dasabuvir; paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin; VIEKIRA PAK®; VIEKIRA PAK-RBV®
• Pertussis vaccine-acellular, combined with diptheria and tetanus toxoids; 0.5 ml vial, 1; Tripacel®
• Pneumococcal conjugate vaccine (13-valent); 0.5 mL injection; Prevenar 13®
• Ponatinib; 15 mg tablet, 60; 45 mg tablet, 30; Iclusig®
• Quadrivalent influenza vaccine; 0.5 ml pre-filled syringe, 5; 0.5 ml pre-filled syringe, 10; 0.25 ml pre-filled syringe, 5; 0.25 ml pre-filled syringe, 10; Fluquadri®
• Ribavirin; 400 mg tablet, 28; 600 mg tablet, 28; Ibavyr®
• Riociguat; 0.5 mg tablet, 42; 0.5 mg tablet, 84; 1 mg tablet, 42; 1 mg tablet, 84; 1.5 mg tablet, 42; 1.5 mg tablet, 84; 2 mg tablet, 42; 2 mg tablet, 84; 2.5 mg tablet, 42; 2.5 mg tablet, 84; Adempas®
• Rituximab; injection for infusion; 500mg/50mL; Mabthera®
• Rivastigmine; 13.3 mg/24 hours patch, 30; Exelon®
• Saxagliptin; 2.5 mg tablet, 28; 5.0 mg tablet, 28; Onglyza®
• Saxagliptin and metformin XR; Kombiglyze® XR
• Simeprevir, capsule, 150mg, OLYSIO®
• Sitagliptin; sitagliptin and metformin; sitagliptin and metformin XR; Januvia®; Janumet®; Janumet XR®
• Sitagliptin; sitagliptin and metformin; sitagliptin and metformin XR; Januvia®; Janumet®; Janumet XR®
• Strontium ranelate; 2 g granules for oral suspension, 28 x 2g sachets; Protos®
• Sucroferric oxyhydroxide; Iron (as sucroferric oxyhydroxice) 500 mg tablet: chewable, 90; Velphoro®
• Testosterone; testosterone 1% (50 mg/5 g) gel, 30 x 5 g sachets; testosterone 2% (30 mg/1.5 mL actuation) transdermal solution, 60 actuations; testosterone 2.5 mg/24 hours patch, 60; testosterone 5 mg/24 hours patch, 30
• Tiotropium bromide; tiotropium 2.5 microgram inhalation: solution for, 60 actuations, Spiriva®, Respimat®
• Tiotropium bromide with olodaterol hydrochloride; tiotropium 2.5 microgram/actuation + olodaterol 2.5 microgram/actuation inhalation: solution for, 60 actuations; Spiolto® Respimat®
• Trastuzumab; solution for subcutaneous injection, 600 mg/5 mL, 1; Herceptin®
• Trastuzumab; powder for I.V. infusion, 60 mg vial,1; powder for I.V. infusion, 150 mg vial, 1; Herceptin®
• Triglycerides medium chain formula; oral liquid: powder for, 400 g; Peptamen Junior®
• Ustekinumab; 45 mg/0.5 mL injection vial,1; Stelara®
• Removing (delisting) over the counter medicines from the PBS
• Ipilimumab; Incidence and costs of treating adverse events